Please use this identifier to cite or link to this item: https://hdl.handle.net/10216/155603
Full metadata record
DC FieldValueLanguage
dc.creatorRocha, DMGC
dc.creatorViveiros, M
dc.creatorSaraiva, M
dc.creatorOsório, NS
dc.date.accessioned2023-12-11T15:45:36Z-
dc.date.available2023-12-11T15:45:36Z-
dc.date.issued2021
dc.identifier.issn2073-4425
dc.identifier.urihttps://hdl.handle.net/10216/155603-
dc.description.abstractThe airborne pathogen Mycobacterium tuberculosis is responsible for a present major public health problem worsened by the emergence of drug resistance. M. tuberculosis has acquired and developed streptomycin (STR) resistance mechanisms that have been maintained and transmitted in the population over the last decades. Indeed, STR resistant mutations are frequently identified across the main M. tuberculosis lineages that cause tuberculosis outbreaks worldwide. The spread of STR resistance is likely related to the low impact of the most frequent underlying mutations on the fitness of the bacteria. The withdrawal of STR from the first-line treatment of tuberculosis potentially lowered the importance of studying STR resistance. However, the prevalence of STR resistance remains very high, could be underestimated by current genotypic methods, and was found in outbreaks of multi-drug (MDR) and extensively drug (XDR) strains in different geographic regions. Therefore, the contribution of STR resistance to the problem of tuberculosis drug resistance should not be neglected. Here, we review the impact of STR resistance and detail well-known and novel candidate STR resistance mechanisms, genes, and mutations. In addition, we aim to provide insights into the possible role of STR resistance in the development of multi-drug resistant tuberculosis.
dc.description.sponsorshipThis research was funded by NORTE-01-0145-FEDER-000039, NORTE-01-0145-FEDER-000013, and NORTE-01-0145-FEDER-00002, supported by Norte Portugal Regional Operational Program (NORTE 2020), under the PORTUGAL 2020 Partnership Agreement, through the European Regional Development Fund (ERDF). It was also funded through the Foundation for Science and Technology (FCT)—project FCT IF/00474/2014, UIDB/50026/2020, and UIDP/50026/2020. DR was funded by FCT Ph.D. scholarships (grant number SFRH/BD/135422/2017). DR was partially funded by the PGCD—Graduate Program Science for Development. MS is supported by FCT through the Estimulo ao Emprego Científico.
dc.language.isoeng
dc.publisherMDPI
dc.relation.ispartofGenes, vol.12(12):2003
dc.rightsopenAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectAntibiotic
dc.subjectDrug-resistance
dc.subjectLineages
dc.subjectMultidrug-resistance
dc.subjectMutations
dc.subjectMycobacterium
dc.subjectResistance level
dc.subjectStreptomycin
dc.subjectTuberculosis
dc.titleThe neglected contribution of streptomycin to the tuberculosis drug resistance problem
dc.typeArtigo em Revista Científica Internacional
dc.contributor.uportoInstituto de Investigação e Inovação em Saúde
dc.identifier.doi10.3390/genes12122003
dc.relation.publisherversionhttps://www.mdpi.com/2073-4425/12/12/2003
Appears in Collections:I3S - Artigo em Revista Científica Internacional

Files in This Item:
File Description SizeFormat 
10.3390-genes12122003.pdf32.5 MBAdobe PDFThumbnail
View/Open


This item is licensed under a Creative Commons License Creative Commons